GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioTelemetry Inc (NAS:BEAT) » Definitions » Beneish M-Score

BioTelemetry (BioTelemetry) Beneish M-Score : -2.50 (As of Apr. 28, 2024)


View and export this data going back to 2008. Start your Free Trial

What is BioTelemetry Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.5 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for BioTelemetry's Beneish M-Score or its related term are showing as below:

BEAT' s Beneish M-Score Range Over the Past 10 Years
Min: -4.02   Med: -2.28   Max: -0.52
Current: -2.5

During the past 13 years, the highest Beneish M-Score of BioTelemetry was -0.52. The lowest was -4.02. And the median was -2.28.


BioTelemetry Beneish M-Score Historical Data

The historical data trend for BioTelemetry's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioTelemetry Beneish M-Score Chart

BioTelemetry Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.62 -1.52 -1.93 -2.06 -1.65

BioTelemetry Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.00 -1.65 -1.94 -2.41 -2.50

Competitive Comparison of BioTelemetry's Beneish M-Score

For the Diagnostics & Research subindustry, BioTelemetry's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioTelemetry's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BioTelemetry's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where BioTelemetry's Beneish M-Score falls into.



BioTelemetry Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of BioTelemetry for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2004+0.528 * 1.009+0.404 * 0.943+0.892 * 1.0189+0.115 * 1.0073
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0565+4.679 * -0.061098-0.327 * 0.8491
=-2.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep20) TTM:Last Year (Sep19) TTM:
Total Receivables was $88.6 Mil.
Revenue was 114.655 + 99.109 + 113.031 + 112.034 = $438.8 Mil.
Gross Profit was 68.987 + 61.527 + 70.508 + 69.917 = $270.9 Mil.
Total Current Assets was $190.4 Mil.
Total Assets was $737.1 Mil.
Property, Plant and Equipment(Net PPE) was $63.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $45.4 Mil.
Selling, General, & Admin. Expense(SGA) was $176.5 Mil.
Total Current Liabilities was $68.0 Mil.
Long-Term Debt & Capital Lease Obligation was $158.1 Mil.
Net Income was 6.714 + 2.281 + 7.109 + 1.576 = $17.7 Mil.
Non Operating Income was -9.963 + -12.569 + -7.173 + -13.962 = $-43.7 Mil.
Cash Flow from Operations was 21.889 + 56.842 + 12.703 + 14.948 = $106.4 Mil.
Total Receivables was $72.5 Mil.
Revenue was 111.291 + 111.803 + 103.979 + 103.603 = $430.7 Mil.
Gross Profit was 69.339 + 70.24 + 64.778 + 63.946 = $268.3 Mil.
Total Current Assets was $150.1 Mil.
Total Assets was $676.2 Mil.
Property, Plant and Equipment(Net PPE) was $55.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $40.4 Mil.
Selling, General, & Admin. Expense(SGA) was $163.9 Mil.
Total Current Liabilities was $61.1 Mil.
Long-Term Debt & Capital Lease Obligation was $183.2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(88.638 / 438.829) / (72.469 / 430.676)
=0.201988 / 0.168268
=1.2004

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(268.303 / 430.676) / (270.939 / 438.829)
=0.622981 / 0.617414
=1.009

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (190.381 + 63.138) / 737.095) / (1 - (150.143 + 55.608) / 676.164)
=0.656057 / 0.695708
=0.943

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=438.829 / 430.676
=1.0189

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(40.445 / (40.445 + 55.608)) / (45.35 / (45.35 + 63.138))
=0.42107 / 0.418019
=1.0073

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(176.461 / 438.829) / (163.917 / 430.676)
=0.402118 / 0.380604
=1.0565

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((158.077 + 68.012) / 737.095) / ((183.173 + 61.077) / 676.164)
=0.30673 / 0.361229
=0.8491

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(17.68 - -43.667 - 106.382) / 737.095
=-0.061098

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

BioTelemetry has a M-score of -2.54 suggests that the company is unlikely to be a manipulator.


BioTelemetry Beneish M-Score Related Terms

Thank you for viewing the detailed overview of BioTelemetry's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BioTelemetry (BioTelemetry) Business Description

Traded in Other Exchanges
N/A
Address
1000 Cedar Hollow Road, Suite 102, Malvern, PA, USA, 19355
BioTelemetry Inc provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. It operates under healthcare, technology, and research segments. The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. The Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials and the Technology segment, focuses on the development, manufacturing, testing, and marketing of cardiovascular and blood glucose monitoring devices to medical companies, clinics and hospitals.
Executives
Kirk E Gorman director 367 SOUTH GULPH ROAD, KING PRUSSIA PA 19406
Stephen Rietiker director C/O BIOTELEMETRY, INC., 1000 CEDAR HOLLOW RD. SUITE 102, MALVERN PA 19355
Tiffany Olson director C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Joseph A. Frick director ONE COMMERCE SQUARE 2005 MARKET ST., SUITE 3300 19103 PR 19073
Laura N. Dietch director 1000 CEDAR HOLLOW RD. SUITE 102 MALVERN PA 19355
Anthony James Conti director 76 GOLFVIEW DRIVE, IVYLAND PA 18974
Rebecca W Rimel director 345 PARK AVENUE, NEW YORK NY 10154
Robert J. Rubin director 7901 SPRINGER ROAD, BETHESDA MD 20817
Hill Colin director 196 BROADWAY CAMBRIDGE MA 02139
Andrei G Stoica officer: SVP & CTO 1000 CEDAR HOLLOW ROAD, MALVERN PA 19355
Joseph H Capper director, officer: President & CEO BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Manish Wadhwa officer: SVP & CMO 1000 CEDAR HOLLOW ROAD MALVERN PA 19355
Fred Broadway officer: President BioTel Heart BIOTELEMETRY, INC. 1000 CEDAR HOLLOW ROAD, #102 MALVERN PA 19355
Daniel Wisniewski officer: SVP, Technical Operations BIOTELEMETRY, INC. 1000 CEDAR HOLLOW ROAD, #102 MALVERN PA 19355
Heather C Getz officer: EVP, CFO & CAO BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355